Tet2 is required to resolve inflammation by recruiting Hdac2 to specifically repress IL-6
Open accessThe DOI matches its Crossref record; 30 of the 30 references it cites were found in a registry or an index; 1 of the 24 sources its claims cite were checked for support.
Abstract
Epigenetic modifiers have fundamental roles in defining unique cellular identity through the establishment and maintenance of lineage-specific chromatin and methylation status. Several DNA modifications such as 5-hydroxymethylcytosine (5hmC) are catalysed by the ten eleven translocation (Tet) methylcytosine dioxygenase family members, and the roles of Tet proteins in regulating chromatin architecture and gene transcription independently of DNA methylation have been gradually uncovered. However, the regulation of immunity and inflammation by Tet proteins independent of their role in modulating DNA methylation remains largely unknown. Here we show that Tet2 selectively mediates active repression of interleukin-6 (IL-6) transcription during inflammation resolution in innate myeloid cells, including dendritic cells and macrophages. Loss of Tet2 resulted in the upregulation of several inflammatory mediators, including IL-6, at late phase during the response to lipopolysaccharide challenge. Tet2-deficient mice were more susceptible to endotoxin shock and dextran-sulfate-sodium-induced colitis, displaying a more severe inflammatory phenotype and increased IL-6 production compared to wild-type mice. IκBζ, an IL-6-specific transcription factor, mediated specific targeting of Tet2 to the Il6 promoter, further indicating opposite regulatory roles of IκBζ at initial and resolution phases of inflammation. For the repression mechanism, independent of DNA methylation and hydroxymethylation, Tet2 recruited Hdac2 and repressed transcription of Il6 via histone deacetylation. We provide mechanistic evidence for the gene-specific transcription repression activity of Tet2 via histone deacetylation and for the prevention of constant transcription activation at the chromatin level for resolving inflammation.
Overview
CoChat Summary
TL;DR
Tet2 actively represses Il6 transcription during the late phase of LPS-driven inflammation in myeloid cells by recruiting Hdac2 to the Il6 promoter, independent of DNA methylation. Tet2 loss prolongs IL-6 production and worsens endotoxin shock and DSS-induced colitis in mice.
Key findings
- In Tet2-deficient or Tet2-silenced dendritic cells and macrophages, the early LPS-induced rise in Il6 mRNA before 4 h was largely unchanged, but after 8 h Il6 mRNA remained elevated while control cells declined; IL-6 protein also increased, whereas Tnfa levels were similar. Tet3 silencing barely affected Il6.
- Tet2-deficient mice produced more IL-6 after systemic LPS, especially late, and showed worse lung tissue damage; in DSS colitis they had greater weight loss, higher IL-6, more inflammatory cell infiltration, and mucosal disruption. In Tet2-deficient BMDC, 22 genes were downregulated and 13 upregulated; 12 of the upregulated genes were TLR-induced, including Il6.
- IκBζ interacted with Tet2 and was required for Tet2 binding to the Il6 promoter at late LPS phase. IκBζ overexpression increased Il6 early but reduced it late, and Tet2 loss impaired this late repression.
- Tet2 associated with Hdac1/Hdac2 through its core-DSBH domain. Hdac2 binding at the Il6 promoter fell early and returned late; Hdac2 knockdown increased Il6 transcription and histone acetylation at 10 h, with Hdac1 compensation by 12 h. Catalytically mutant Tet2 still repressed Il6, and Tet2 loss reduced Hdac2 binding and late histone deacetylation.
Methods
- Mouse models included C57BL/6, Tet2fl/fl, Tet2-deficient, and Lyz2-Cre myeloid-specific Tet2-deficient mice; human monocytes came from healthy donors. Cells studied included BMDC, BMM, peritoneal macrophages, and splenic T, B, and NK cells, with LPS at 100 ng/ml; in vivo models were endotoxin shock and DSS colitis.
- Assays included RNA-seq, qPCR, ELISA, immunoblot, immunoprecipitation, co-IP with LC-MS/MS, ChIP and re-ChIP, luciferase reporters, siRNA knockdown, overexpression, and a GAL4-based recruitment assay.
- Statistics used unpaired Student’s t-tests with *P < 0.05 and P < 0.01; error bars were s.e.m. or s.d.; data were from triplicate technical or biological replicates and representative of three independent experiments.
Limitations
- The paper states that animal studies did not randomize by weight or sex and did not use blinding, and that sample size was not predetermined by a statistical method. It also states that HEK293T cells were not authenticated or tested for mycoplasma.
- Evident from the text: Hdac2 knockdown effects were transient because Hdac1 appeared to compensate by 12 h, complicating conclusions about Hdac2-specific repression.
- Evident from the text: many mechanistic experiments relied on overexpression or siRNA in HEK293T or primary cells, and the in vivo work used two inflammatory models; the authors note that additional Tet2-repressed mediators may exist in tissue-resident immune cells.
Model-written summary. Check it against the paper before relying on it.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
1 Valid · 0 Not valid · 16 Not checked · 86 Own results and interpretations
Every source the paper cites for this claim was checked and supports it.
In the paper
“MS-275 strongly inhibits Hdac1/2 over Hdac3 (ref. 19)”
§ Tet2 is required to resolve inflammation by recruiting Hdac2 to specifically repress IL-6 > Abstract
What the sources say
- Supportedcites [19] Inoue, S., Mai, A., Dyer, M. J. & Cohen, G. M. Inhibition of histone deacetylase class I but not class II is critical for the sensitization of leukemic cells to tumor necrosis factor-related apoptosis-inducing ligand-induced apoptosis. Cancer Res. 66, 6785–6792 (2006) source
In the Results section 'Expression of HDACs in CLL cells and various cell lines', our copy reports that MS-275 (1-2.5 micromol/L) inhibited HDAC1 and HDAC2 activities by ~50-70% whereas 1 micromol/L did not inhibit HDAC3 (~20% only at 2.5 micromol/L), and explicitly frames the experiment as confirming that 'MS-275 was selectively inhibiting HDAC1 and HDAC2 rather than HDAC3'. The same section also states MS-275 preferentially inhibits HDAC1 (IC50 ~0.3 micromol/L) versus HDAC3 (IC50 ~8 micromol/L), though that IC50 comparison is itself credited to ref. 32; the paper's own immunoprecipitation/activity data carry the claim. Thus the paraphrase 'strongly inhibits Hdac1/2 over Hdac3' matches what this source attributes to MS-275. (LLM, conf=0.86)
boostedstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Supported
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“overexpressed Tet2 recruited more endogenous Hdac2 to the Il6 promoter”
§ Tet2 is required to resolve inflammation by recruiting Hdac2 to specifically repress IL-6 > Abstract
plainstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“Attenuated histone deacetylation in Tet2-deficient cells was also observed at late phase during LPS response”
§ Tet2 is required to resolve inflammation by recruiting Hdac2 to specifically repress IL-6 > Abstract
plainstates an association- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“loss of Tet2 caused higher expression of IFN-γ in activated CD8+ T cells”
§ Tet2 is required to resolve inflammation by recruiting Hdac2 to specifically repress IL-6 > Abstract
plainstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“Loss of Tet2 barely affects TLR4 signalling pathways”
§ Tet2 is required to resolve inflammation by recruiting Hdac2 to specifically repress IL-6 > Extended Data
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
45 more claims
Create a free account to see all 103 claims and to verify the 15 references still open.
- It may state two separate claims as one. 31
- Probably not a substantial claim. 28
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“mice deficient in Tet2 developed more severe inflammation in several tissues upon challenge with bacterial endotoxin”
From Clonal hematopoiesis in human aging and disease (2019) · cites this paper as [91]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“this effect on Il6 expression was independent of the catalytic function of Tet2”
From Clonal hematopoiesis in human aging and disease (2019) · cites this paper as [91]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“loss of TET2, an enzyme that catalyzes DNA demethylation, results in prolonged and high expression of proinflammatory cytokines, including IL-6 [180].”
From Transition from inflammation to proliferation: a critical step during wound healing (2016) · cites this paper as [180]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“As CHIP-associated mutations are known to alter the development and function of myeloid cells”
From Clonal hematopoiesis is associated with protection from Alzheimer’s disease (2023) · cites this paper as [14]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“These results contrast with findings in peripheral macrophages after intraperitoneal injection in vivo (Zhang et al., 2015).”
From TET2 Regulates the Neuroinflammatory Response in Microglia (2019) · cites this paper as Zhang et al., 2015
Experimental — accuracy not yet measured
20 more claims about this paper
Create a free account to see every claim other papers make about this one.
Citations
Cites
Conversion of 5-Methylcytosine to 5-Hydroxymethylcytosine in Mammalian DNA by MLL Partner TET1
Tahiliani, M., Koh, K. P., Shen, Y., Pastor, W. A., Bandukwala, H., Brudno, Y., Agarwal, S., Iyer, L. M., Liu, D. R., Aravind, L., et al. (2009) · Science · doi:10.1126/science.1170116 · Cited by 5,836
Cytokines in inflammatory bowel disease
Neurath, M. F. (2014) · Nature Reviews Immunology · doi:10.1038/nri3661 · Cited by 2,706
IL-6 as a keystone cytokine in health and disease
Hunter, C. A., & Jones, S. A. (2015) · Nature Immunology · doi:10.1038/ni.3153 · Cited by 2,511
Ito, S., D’Alessio, A. C., Taranova, O. V., Hong, K., Sowers, L. C., & Zhang, Y. (2010) · Nature · doi:10.1038/nature09303 · Cited by 2,373
TET enzymes, TDG and the dynamics of DNA demethylation
Kohli, R. M., & Zhang, Y. (2013) · Nature · doi:10.1038/nature12750 · Cited by 1,623
Suppression of inflammation by a synthetic histone mimic
Nicodeme, E., Jeffrey, K. L., Schaefer, U., Beinke, S., Dewell, S., Chung, C.-W., Chandwani, R., Marazzi, I., Wilson, P., Coste, H., et al. (2010) · Nature · doi:10.1038/nature09589 · Cited by 1,563
Gene-specific control of inflammation by TLR-induced chromatin modifications
Foster, S. L., Hargreaves, D. C., & Medzhitov, R. (2007) · Nature · doi:10.1038/nature05836 · Cited by 1,344
Tet2 loss leads to increased hematopoietic stem cell self-renewal and myeloid transformation
Moran-Crusio, K., Reavie, L., Shih, A., Abdel-Wahab, O., Ndiaye-Lobry, D., Lobry, C., Figueroa, M. E., Vasanthakumar, A., Patel, J., Zhao, X., et al. (2011) · Cancer Cell · doi:10.1016/j.ccr.2011.06.001 · Cited by 1,339
Self-citationImpaired hydroxylation of 5-methylcytosine in myeloid cancers with mutant TET2
Ko, M., Huang, Y., Jankowska, A. M., Pape, U. J., Tahiliani, M., Bandukwala, H. S., An, J., Lamperti, E. D., Koh, K. P., Ganetzky, R., et al. (2010) · Nature · doi:10.1038/nature09586 · Cited by 1,213
Distinct Effects of T-bet in T H 1 Lineage Commitment and IFN-γ Production in CD4 and CD8 T Cells
Szabo, S. J., Sullivan, B. M., Stemmann, C., Satoskar, A. R., Sleckman, B. P., & Glimcher, L. H. (2002) · Science · doi:10.1126/science.1065543 · Cited by 1,172
Cited by
Items 601–700 of 797
Duan, Y., Yuan, C. L., Suo, X., Cao, L., Kong, X., Li, X., Zheng, H., & Wang, Q. (2022) · Journal of Medical Virology · doi:10.1002/jmv.27673 · Cited by 5
“TET2 has been reported to suppress inflammation gene expression independent of catalytic activity.(39) Reconstitution experiments in this study showed TET2 participates in IFN‐I signaling dependent on catalytic activity (Figure 3).”
BackgroundSelf-citationTen-Eleven-Translocation Genes in Cancer
Wang, Y., Wang, X., & Lü, J. (2023) · Cancer treatment and research · doi:10.1007/978-3-031-45654-1_11 · Cited by 5
Liu, K., & Xu, Y. (2023) · Clinical and Experimental Otorhinolaryngology · doi:10.21053/ceo.2023.01340 · Cited by 5
“TET2 has also been shown to bind and recruit HDAC1/2, facilitating histone deacetylation and suppressing IL-6 expression during the resolution phase of inflammation in innate myeloid cells [30].”
BackgroundTen-eleven translocation-2-mediated macrophage activation promotes liver regeneration
Chen, Y., Meng, L., Xu, N., Chen, H., Wei, X., Lu, D., Wang, S., & Xu, X. (2024) · Cell Communication and Signaling · doi:10.1186/s12964-023-01407-7 · Cited by 5
“Tet2 binds and recruits histone deacetylase (HDAC1/2) in an enzymatic activity-independent manner to facilitate histone deacetylation and suppress IL-6 and IL-1β expressions during inflammation resolution in innate myeloid cells and macrophages [21, 22].”
BackgroundHe, H., Wen, Y., Yu, H., Liu, J., Huo, Q., Jin, W., Wang, Z., Du, G., Du, J., Wang, H., et al. (2024) · Genes & Diseases · doi:10.1016/j.gendis.2024.101397 · Cited by 5
Self-citationImmune‐dysregulation harnessing in myeloid neoplasms
Sharifi, M. J., Xu, L., Nasiri, N., Ashja‐Arvan, M., Soleimanzadeh, H., & Ganjalıkhani-Hakemi, M. (2024) · Cancer Medicine · doi:10.1002/cam4.70152 · Cited by 5
Zhuang, Q., Jin, S., Wang, W., Wang, Y., Tong, H., Liu, Z., & Sun, J. (2024) · Trends in Molecular Medicine · doi:10.1016/j.molmed.2024.10.005 · Cited by 7
Brown, A. P. C., Parameswaran, S., Cai, L. P., Elston, S., Pham, C., Barski, A., Weirauch, M. T., & Ji, H. (2025) · Environmental Epigenetics · doi:10.1093/eep/dvaf007 · Cited by 6
Reversing epigenetic repression of transposable elements for improving tumor immunogenicity
Wang, X., Zhang, Q., & Cao, X. (2022) · 癌症:英文版 · doi:10.1002/cac2.12261 · Cited by 5
“Chromatin modifiers can mediate epigenetic regulation in a catalytic activity-independent strategy [7].”
BackgroundSelf-citationVitamin C in Cancer Therapeutics and Metastasis.
Xi, D. (2019) · PubMed · doi:10.29011/2575-8241.001127 · Cited by 8
“TET2 can suppress the IL-6 production [15].”
Flagellin induces innate immune genes in bronchial epithelial cells in vivo: Role of TET2
Qin, W., Brands, X., Veer, C. V. ′., de Vos, A. F., Scicluna, B. P., & van der Poll, T. (2021) · Scandinavian Journal of Immunology · doi:10.1111/sji.13046 · Cited by 5
Fleming, A., Knatko, E. V., Li, X., Zoch, A., Heckhausen, Z., Stransky, S., Brenes, A. J., Sidoli, S., Hájková, P., O’Carroll, D., et al. (2024) · Genes & Development · doi:10.1101/gad.352176.124 · Cited by 5
Self-citationQuang, V. T., Wagner‐Ballon, O., & Sloma, I. (2024) · Leukemia & lymphoma/Leukemia and lymphoma · doi:10.1080/10428194.2024.2378816 · Cited by 4
“…triggered by infections. indeed, tet2 is also involved in the formation of complexes regulating chromatin conformation by recruiting the enzyme O-linked N-acetylglucosamine transferase (OGt) and histone deacetylase (Hdacs) to regulate transcription and histone changes at specific loci [66, 67].”
Zhao, Y., Yuan, W., Feng, Y. M., & Zhao, R. (2024) · International Journal of Molecular Sciences · doi:10.3390/ijms25189894 · Cited by 4
“For instance, DNA demethylase ten-eleven translocation 2 (TET2) recruits histone deacetylase HDAC2 to repress IL-6 transcription via histone deacetylation during the resolution phase of inflammation in innate myeloid cells, including dendritic cells and macrophages [10].”
BackgroundLim, K. S., Kan, W. L., Nair, P. C., Kutyna, M., Lopez, A. F., Hercus, T. R., Ross, D. M., Lane, S., Fong, C. Y., Brown, A. L., et al. (2024) · PLoS ONE · doi:10.1371/journal.pone.0310641 · Cited by 7
The advances in acetylation modification in senescence and aging-related diseases
Xu, M., Wang, W., Lu, S., Xiong, M., Zhao, T., Yu, Y., Song, C., Yang, J., Zhang, N., Cao, L., et al. (2025) · Frontiers in Physiology · doi:10.3389/fphys.2025.1553646 · Cited by 6
“…2014; Donnarumma et al., 2022; Min et al., 2021; Wang et al., 2023; Wang et al., 2008; Chang et al., 2011; Aghdassi et al., 2012; Gao et al., 2020; Zhang et al., 2015; Chen et al., 2009; Lin and Wu, 2020; Gaddelapati et al., 2022; Grégoire et al., 2007; Meng et al., 2016; Deardorff et al., 2012;…”
Green, H. L. H., Sum, H., Sinha, P., Visnagri, A., Lee, S. H., Baffour-Kyei, A., Lee, H., Santos, F. G. D. A., Theofilatos, K., & Brewer, A. C. (2025) · Journal of Biological Chemistry · doi:10.1016/j.jbc.2025.110520 · Cited by 4
TLR2 agonism suppresses myeloid leukemogenesis by reprogramming leukemia stem cells
Lawler, M. E., Romer-Seibert, J. S., Bowman, M. S., Mitra, R., Eischen, C. M., Bowman, R. L., & Meyer, S. E. (2025) · Blood Advances · doi:10.1182/bloodadvances.2025017018 · Cited by 4
Cigarette smoke exposure promotes nasal polyp formation through down-regulating TET2
Liu, P., Qin, D., Chen, S., Liu, K., Huang, J., Xu, Y., Wu, X., Lv, H., Gu, T., Liu, D., et al. (2025) · Ecotoxicology and Environmental Safety · doi:10.1016/j.ecoenv.2025.119244 · Cited by 4
Carter, P., Kitt, L., Rodgers, A., Figg, N. L., Zhou, A., Zhu, C., Wang, Z., Libby, P., Burgess, S., Vassiliou, G. S., et al. (2025) · JCI Insight · doi:10.1172/jci.insight.200334 · Cited by 8
“Several studies report increased IL-1 β release from Tet2 , Dnmt3a , and Jak2 mutant M ɸ s (16, 20, 21), while others show no difference (5, 19, 24, 29–31).”
Myelodysplastic syndrome progress to acute myeloid leukemia: new insights and updates
Zhang, Y., Yan, L., Fan, C., Zhao, B., Chen, M., Hao, X., Zhu, G., Jia, Y., Xu, Y., & Shi, Z. (2026) · Frontiers in Immunology · doi:10.3389/fimmu.2026.1769944 · Cited by 6
TET2, an “ambiguous” player in inflammation
Espinosa-Oliva, A. M., & Burguillos, M. Á. (2020) · Neural Regeneration Research · doi:10.4103/1673-5374.274338 · Cited by 5
“Regarding the regulation of immune functions, TETs have been described as decisive players in various aspects of the inflammatory response driven by myeloid and lymphoid cells (Ichiyama et al., 2015; Zhang et al., 2015; Carrillo-Jimenez et al., 2019; Lio and Rao, 2019).”
BackgroundMethodResultInfluentialBiological insights into the role of TET2 in T cell lymphomas
Carty, S. A. (2023) · Frontiers in Oncology · doi:10.3389/fonc.2023.1199108 · Cited by 6
“In myeloid cells, TET2 represses inflammatory gene expression (53) with increased IL-6, IL-1b and arginase 1 in TET2-deficient macrophages (54, 55).”
BackgroundExploring the intricate cross-talk between clonal expansion and the bone marrow niche
Ngo, S. D., Papazoglou, D., Encabo, H. H., & Bonnet, D. A. (2024) · Frontiers in Hematology · doi:10.3389/frhem.2024.1334807 · Cited by 5
Gupta, S., Rishi, V., Elipilla, P., & Aggarwal, A. (2025) · International Journal of Biological Macromolecules · doi:10.1016/j.ijbiomac.2025.141596 · Cited by 5
Yu, Z., Vlasschaert, C., & Natarajan, P. (2025) · Journal of the American Society of Nephrology · doi:10.1681/asn.0000000739 · Cited by 4
Myelodysplastic Neoplasms (MDS): Pathogenesis and Therapeutic Prospects
Li, X., Zou, C., Xiang, X., Zhao, L., Chen, M., Yang, C., & Wu, Y. (2025) · Biomolecules · doi:10.3390/biom15060761 · Cited by 8
“The absence of TET2 leads to increased expression of IL-6 and IL-1 β in response to inflammatory stimuli, enhancing innate immune responses in MDS [181,182].”
Self-citationBird, L. (2015) · Nature reviews. Immunology · doi:10.1038/nri3912 · Cited by 4
Patysheva, M. R., Stakheyeva, M. N., Larionova, I., Fedorov, A. A., Kzhyshkowska, J. G., & Чердынцева, Н. В. (2019) · Experimental Oncology · doi:10.32471/exp-oncology.2312-8852.vol-41-no-3.13597 · Cited by 5
Zhang, W., Chen, Z., Yi, K., Su, G., Liu, Y., Deng, Y., Zhang, Y., Cao, Q., Pu, Y., Luo, X., et al. (2023) · Clinical Immunology · doi:10.1016/j.clim.2023.109323 · Cited by 4
Self-citationRegulators of clonal hematopoiesis and physiological consequences of this condition
Park, E., Evans, M. A., & Walsh, K. X. (2023) · The Journal of Cardiovascular Aging · doi:10.20517/jca.2023.39 · Cited by 6
Reshaping the Landscape of the Genome: Toolkits for Precise DNA Methylation Manipulation and Beyond
Zhu, C., Hao, Z., & Liu, D. (2023) · JACS Au · doi:10.1021/jacsau.3c00671 · Cited by 5
Epigenetics and Infectious Disease: State-of-the-Art and Perspectives in New Generation Therapies
Valeria, M., Daniela, D., Francesca, M., Nicola, P., & Luigi, A. (2018) · OBM Genetics · doi:10.21926/obm.genet.1804048 · Cited by 7
Privileged Scaffolds Targeting Bromodomain-containing Protein 4
Wang, R., Wang, Y.-A., Xu, Y., & Shi, L. (2022) · Current Topics in Medicinal Chemistry · doi:10.2174/1568026622666220209143949 · Cited by 4
Hayashi, T., Eto, K., & Kadoya, Y. (2022) · Differentiation · doi:10.1016/j.diff.2022.05.001 · Cited by 5
Hu, K., Li, Y., Jin, L., Chen, Y., Chen, L., Zhang, Y., Huang, M., Ding, Y., Yin, H., Liang, M., et al. (2022) · Contrast Media & Molecular Imaging · doi:10.1155/2022/7511345 · Cited by 4
“0is is consistent with several reports suggesting that acetylation modification is involved in inflammatory disorder development [10, 11].”
BackgroundYee, K. M., Shuai, R. W., Liu, B., Huynh, C., Niu, C. S., Lee, H. R., Lee, M. S., Wen, J., Zou, J., Wu, J., et al. (2021) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2021.09.07.459280 · Cited by 4
Clonal hematopoiesis of indeterminate potential and heart failure
Lyasnikova, E. A., Ivanchenko, L. Y., Козлова, С. Н., Sitnikova, M. Y., Kostareva, A. A., & Shlyakhto, E. V. (2024) · Russian Journal of Cardiology · doi:10.15829/1560-4071-2024-6016 · Cited by 3
Impact of Clonal Hematopoiesis on Solid Tumor Progression Following Radiation Therapy
Tao, J. J., Setton, J. S., Vela, P. S., Safonov, A. M., Comen, E. A., Braunstein, L. Z., Reis-Filho, J. S., Riaz, N., Powell, S. N., Levine, R. L., et al. (2025) · JCO Precision Oncology · doi:10.1200/po-24-00548 · Cited by 7
Self-citationRetinoic acid and ascorbate synergize to suppress myeloid leukemia via TET2 activation
Leesang, T. E., Brabson, J. P., Yap, Y. S., Barbieri, D. A., Klimas, A. S., Pinzone, J., Ahearn, E. L., Lam, M. Q., Lyon, P. D., Swirski, A., et al. (2025) · Cell Reports · doi:10.1016/j.celrep.2025.116379 · Cited by 5
“75 Interestingly, upon combination treatment with ATRA and ascorbate, we observed reduced accessibility for AP-1 transcription factors FOS and JUN, which are normally activated in response to inflammatory cytokine signaling and sustain aberrant AML self-renewal and stem cell growth.”
Of Barriers and Loops—How Evolution Limits Most Cancer Risks to Older Ages
Dominici, M. D., & DeGregori, J. V. (2026) · Cancer Discovery · doi:10.1158/2159-8290.cd-25-0779 · Cited by 4
Gong, Z., Chen, Z., Sang, S., Yang, L., Qin, H., Li, Q., & Jia, Y. (2026) · Free Radical Biology and Medicine · doi:10.1016/j.freeradbiomed.2026.01.019 · Cited by 4
Hu, L., Shen, Q., Gu, Y., Lu, J., Li, Y., Liu, N., Zhang, B., Han, Y., Zhang, Q., & Cao, X. (2026) · Immunity & Inflammation · doi:10.1007/s44466-026-00034-4 · Cited by 6
“TET2 plays essential roles in establishing cell-specific function of myeloid cells and their progenitors [10–12].”
Self-citationEpigenetic mechanisms of inflammatory memory in the central nervous system
Ye, J. J., & Quintana, F. J. (2026) · Nature Immunology · doi:10.1038/s41590-026-02541-3 · Cited by 4
Qin, W., Brands, X., Veer, C. V. ′., de Vos, A. F., Scicluna, B. P., & van der Poll, T. (2022) · Cytokine · doi:10.1016/j.cyto.2022.155876 · Cited by 3
Clonal hematopoiesis, inflammation, and cardiovascular disorders: a mitochondrial connection
Pileri, F., & Natoli, G. (2022) · Trends in Immunology · doi:10.1016/j.it.2022.07.009 · Cited by 3
Zhu, F., Hu, Z., Yu, W., Dai, F., Jing, D., & Zhou, G. (2023) · Journal of Inflammation Research · doi:10.2147/jir.s422057 · Cited by 3
Swaminathan, A. C., Barfield, R., Zhang, M., Povysil, G., Chen, C., Frankel, C. W., Kelly, F. L., McKinney, M. S., Todd, J. L., Allen, A. S., et al. (2023) · BMC Pulmonary Medicine · doi:10.1186/s12890-023-02703-1 · Cited by 4
“Mutations in the genes most frequently identified in CHIP, Tet methylcytosine dioxygenase 2 ( TET2 ) and DNA methyltransferase 3 alpha ( DNMT3A) , have been linked to an increase in pro-inflammatory cytokine/chemokine production and altered immune cell function [6, 11–15].”
BackgroundZhao, X., Hu, C., Chen, X., Ren, S., & Gao, F. (2024) · Biology · doi:10.3390/biology13020082 · Cited by 3
“…plays a role in inflammation resolution by repressing the expression of the inflammatory cytokine IL-6 expression in innate myeloid cells, including dendritic cells and macrophages, through histone deacetylation facilitated by HDAC2 recruitment, a process initiated by the IL-1R-MyD88 pathway [16].”
Higher risk profile among patients with TET2-mutated giant cell arteritis: a cluster analysis
Guédon, A. F., Ouafdi, A., Belfeki, N., Dellal, A., Ghriss, N., Scheen, M., Haidar, F., Espitia, O., Scoazec, J., Fain, O., et al. (2024) · RMD Open · doi:10.1136/rmdopen-2024-004694 · Cited by 4
Genetic evidence for the causal effect of clonal hematopoiesis on pulmonary arterial hypertension
Qiu, J.-Y., Huang, S.-S., Liu, C., Ding, D., Xu, Y., Mao, Y., & Yuan, Y.-D. (2025) · BMC Cardiovascular Disorders · doi:10.1186/s12872-025-04475-4 · Cited by 3
Chronic Myelomonocytic Leukemia Gold Jubilee
Solary, É., & Itzykson, R. (2021) · Hemato · doi:10.3390/hemato2030026 · Cited by 4
“In mouse macrophages, a catalytically dead Tet2 mutant represses Il6 gene transcription, which contributes to the down-regulation an inflammatory reaction [133,134].”
BackgroundMyeloid-Derived Suppressor Cells in Aged Humans
Rauh, M. J., Cook, E. K., & Bowdish, D. M. E. (2019) · Springer eBooks · doi:10.1007/978-3-319-99375-1_96 · Cited by 3
Larocca, C. A., Shanmugam, V., Zemmour, D., Antin, J. H., & Lane, A. A. (2022) · American Journal of Dermatopathology · doi:10.1097/dad.0000000000002231 · Cited by 4
Craven, K. E., & Ewalt, M. D. (2023) · Clinics in Laboratory Medicine · doi:10.1016/j.cll.2023.06.001 · Cited by 3
Clonal hematopoiesis of indeterminate potential: implications for the cardiologists
Sciatti, E., D’Elia, E., Gori, M., Grosu, A., Balestrieri, G., Senni, M., Barbui, T., & Gavazzi, A. (2023) · Journal of Cardiovascular Medicine · doi:10.2459/jcm.0000000000001520 · Cited by 3
Xu, Z., Liu, H., Sun, C., Si, K., Zhao, Y., & Zheng, Z. (2018) · BioMed Research International · doi:10.1155/2018/8610368 · Cited by 4
“As an essential cytokine, IL-6 has a broad range of immune properties relating to inflammation and tissue injury, and it contributes to the clinical evolution of CAD [17, 18]; it exerts its biological activities through IL-6R.”
BackgroundThe Role of TET Proteins in B Cell Biology
Tanaka, S., Ise, W., Baba, Y., & Kurosaki, T. (2020) · Journal of Immunological Sciences · doi:10.29245/2578-3009/2021/1.1202 · Cited by 3
MicroRNA Let-7adf in Tet regulation
Jiang, S. (2019) · Aging · doi:10.18632/aging.102101 · Cited by 3
Stolz, A., Xuan, C., Freitas, C., Chelbi, R., Ait-Ougouram, H., Fandrei, D., Ye, M., Nelson, E., Maillard, C., Bohm, M., et al. (2025) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2025.07.21.665900 · Cited by 4
TET2 promotes UVB-induced cell death by activating RIPK3-MLKL-necroptosis signaling
Long, D., Xu, Y., Li, X., Zeng, Y., Tang, Z., Liu, L., Liu, Y., Zong, X., Yang, S., & Wang, D. (2025) · Chemico-Biological Interactions · doi:10.1016/j.cbi.2025.111550 · Cited by 2
Self-citationYue, Q., Li, Z., Du, Y., Hao, X., Huang, H., Sun, Z., Wang, J., Tao, Y., Yin, H., Pei, K., et al. (2025) · International Immunopharmacology · doi:10.1016/j.intimp.2025.115346 · Cited by 2
Single-Cell Genomics and Somatic Variation in Circulating and Cardiac Resident Cells
Hilal, N., Arava, M., & Choudhury, S. (2026) · Circulation Research · doi:10.1161/circresaha.125.325797 · Cited by 3
Metabolic control of innate immune activation in TET2-mutant clonal hematopoiesis
Kim, P. G., Hergott, C. A., Miller, A. P., Deik, A., Boileau, M., Bullock, K. H., Pierce, K. A., Choy, A. H., Shin, W., McConkey, M. E., et al. (2026) · Cell chemical biology · doi:10.1016/j.chembiol.2026.01.006 · Cited by 3
“2,13 Others have focused on delayed resolution of inflammation or other cytokines such as IL-6 or MIF, implicating histone deacetylase-mediated transcriptional effects 8,14,15 or alterations of NF-κ B transcription factor activity by non-coding RNAs in TET2 KO cells.”
Wei, R., Liu, D., Shu, K., & Zhu, H. (2026) · Drug Resistance Updates · doi:10.1016/j.drup.2026.101444 · Cited by 3
(2016) · Cell · doi:10.1016/j.cell.2016.06.013 · Cited by 2
Factors associated with clonal hematopoiesis and interaction with marrow environment
Nannya, Y. (2022) · Journal of Bone and Mineral Metabolism · doi:10.1007/s00774-022-01380-0 · Cited by 2
“On the other hand, TET2 deficiency induces the maintenance of hyper-inflammatory states through chronic hypersecretion of IL-6 [31].”
BackgroundInfluentialLin, S., Li, Y. E., & Wang, Y. (2025) · Advanced Genetics · doi:10.1002/ggn2.202400047 · Cited by 3
Xie, J., Zhou, D., Shi, Y., & Xu, G. (2025) · Chinese Science Bulletin (Chinese Version) · doi:10.1360/tb-2025-0136 · Cited by 2
Understanding the Crosstalk Between Epigenetics and Immunometabolism to Combat Cancer
Seth, A., & Kar, S. (2022) · Sub-cellular biochemistry/Subcellular biochemistry · doi:10.1007/978-3-031-07634-3_18 · Cited by 3
Vitamin C in Health and Disease: From Redox Biology to Clinical Medicine
Li, Y. R. (2024) · Advances in biochemistry in health and disease · doi:10.1007/978-3-031-55474-2_16 · Cited by 4
Decoding vascular aging: implications for atherosclerosis progression and clinical intervention
Silumbwe, C. W., Ji, X., & Xu, M. (2024) · Exploration of Drug Science · doi:10.37349/eds.2024.00056 · Cited by 4
Understanding Myelodysplasia and Inflammation Through the Lense of VEXAS Syndrome: A Review
Wolff, L., Caratsch, L., Zhao, L., Blum, S., & Comte, D. (2024) · Cells · doi:10.3390/cells13221890 · Cited by 2
Lee, J., An, H., Koh, Y., & Lee, C. (2024) · ERJ Open Research · doi:10.1183/23120541.00292-2024 · Cited by 3
“As an instance of CHIP in COPD pathogenesis, the mutation of the TET2 gene, involved in suppressing inflammation via interleukin-6, heightens susceptibility to toxin exposure and correlates with smoking-induced inflammation and emphysema exacerbation [3, 20].”
Zhou, Y., Zheng, S., Xie, Y., Jing, M., Jiang, M., Li, D., & Liu, A. (2025) · Archives of Biochemistry and Biophysics · doi:10.1016/j.abb.2025.110552 · Cited by 2
Yu, X., Qian, N., & Wang, Y. (2023) · Molecular Biology Reports · doi:10.1007/s11033-022-08118-1 · Cited by 2
Diverse genome‐wide DNA methylation alterations in canine hepatocellular tumours
Asari, Y., Yamazaki, J., Oo, T., Suzuki, T., Aoshima, K., Takeuchi, K., Kinoshita, R., Kim, S., Hosoya, K., Ishizaki, T., et al. (2023) · Veterinary Medicine and Science · doi:10.1002/vms3.1204 · Cited by 2
Bone marrow contribution to the heart from development to adulthood
Sampaio‐Pinto, V., Ruiz‐Villalba, A., Nascimento, D. S., & Pérez-Pomares, J. M. (2020) · Seminars in Cell and Developmental Biology · doi:10.1016/j.semcdb.2020.06.008 · Cited by 2
Carty, S. A., Murga‐Zamalloa, C., & Wilcox, R. A. (2023) · Clinical Lymphoma Myeloma & Leukemia · doi:10.1016/j.clml.2023.04.007 · Cited by 2
Tricarico, R., Madžo, J., Scher, G., Maegawa, S., Jelínek, J., Scher, C., Chang, W., Nicolas, É., Zhou, Y., Slifker, M. J., et al. (2019) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/676445 · Cited by 3
“Previously, TET2 was shown to play a role in inflammation (32), and acute TDG knockdown (21) led to overexpression of genes belonging to inflammatory response senescence-associated secretory phenotype (SASP)(33-35).”
BackgroundCytokines mediated hyperinflammation in SARS-CoV2: An Overview
Ali, L. (2020) · Life and Science · doi:10.37185/lns.1.1.147 · Cited by 3
Lv, H., Gao, Z., Wang, Y., Liu, P., Qin, D., Zhou, H., & Xu, Y. (2022) · PubMed Central · doi:10.2196/preprints.40618 · Cited by 3
Bai, Y., Wang, X., Lin, N., Li, R., Hu, W., Wang, J., Chen, C., Liu, J., Feng, J., & Li, F. (2025) · Frontiers in Cardiovascular Medicine · doi:10.3389/fcvm.2025.1577303 · Cited by 1
Self-citationBasak, S. C., & Gomez, D. A. (2026) · Biomolecules · doi:10.3390/biom16060825 · Cited by 1
“Mechanistically, TET2 can recruit other epigenetic modifiers such as HDAC2 or O-Linked N-Acetylglucosamine (GlcNAc) Transferase to promote gene repression or activation, respectively [153,184].”
Clonal evolution: a landmark of MPN evolution
Maslah, N., Giraudier, S., Cassinat, B., & Kiladjian, J. (2024) · Frontiers in Hematology · doi:10.3389/frhem.2024.1473920 · Cited by 1
Dang, Y., Ma, J., Ling, S., Wang, S., Guo, H., Liu, J., Ji, G., & Xu, J. (2025) · MedComm · doi:10.1002/mco2.70261 · Cited by 2
“The importance of TET1 in the development of embryonic stem cells has been proven [3–5], whereas TET2 has been shown to be pivotal in the progression of inflammatory diseases [6, 7], atherosclerosis [8, 9], diabetes [10], clonal hematopoiesis [8, 11], and cancer [10, 12].”
Self-citationHuang, C., Chen, Y.-Y., Lu, C.-H., Yang, Y.-R., Wu, Y.-Y., Wu, C.-H., Tsai, W.-Y., Lin, M., Tsou, H.-Y., Li, C.-P., et al. (2025) · Journal of the Formosan Medical Association · doi:10.1016/j.jfma.2025.09.039 · Cited by 3
Chen, J.-P., Ke, P., Qiu, X., Xian, Q.-Y., Wu, J.-S., Feng, C., Li, H.-J., Wang, Y., & Zhou, J. (2026) · Annals of Hematology · doi:10.1007/s00277-026-06753-3 · Cited by 1
Chen, D., Wang, Y., Chen, J., Zhang, Y.-F., Dai, Z., & Zou, X.-Y. (2020) · Analytica Chimica Acta · doi:10.1016/j.aca.2020.02.038 · Cited by 1
Pelkey, L. J., Graham, D. M., Zakem, M. H., & Muza–Moons, M. M. (2022) · Cureus · doi:10.7759/cureus.22422 · Cited by 1
“As noted above, TET2 mutations result in upregulated IL-6, and signaling mutations in NRAS/JAK2V617F result in GM-CSF hypersensitivity [14,16].”
BackgroundFoffa, I., Esposito, A., Simonini, L., Berti, S. L., & Vecoli, C. (2025) · Journal of Cardiovascular Development and Disease · doi:10.3390/jcdd12040135 · Cited by 2
“Indeed, many mutations causing clonal expansion of blood stem cell clones also promote increased expression of inflammatory genes in innate immune cells [86,88,89].”
Molecular concepts in hematology and cellular basis of hematopoiesis
Göttgens, B., & Ghiaur, G. (2022) · doi:10.1182/ashsap8.chapter01 · Cited by 1
TET2 might be a therapeutic target for atherosclerosis
Wang, Y., Zhao, D., Lu, P., & Sheng, J. (2015) · International Journal of Cardiology · doi:10.1016/j.ijcard.2015.10.052 · Cited by 1
Self-citationEnhanced glucose metabolism in Tet-deficient mouse embryonic stem cells
Yang, Y., Cavalier, M., Suris, A., Chen, K., An, C., Fan, J., Rivera, L., Fang, S., Guo, L., Zhou, Y., et al. (2024) · Frontiers in Epigenetics and Epigenomics · doi:10.3389/freae.2024.1245823 · Cited by 1
“…the Tet enzymes are known as DNA methylation dioxygenases and are usually associated with transcriptional activation, there have also been reports of Tet proteins exerting a catalytic-independent role to suppress gene expression by partnering with HDAC2 (Zhang et al., 2015; Fuster et al., 2017).”
Kang, C. K., Choi, B., Kim, S., Park, S., Yoon, S. H., Lee, D., Lee, A., Ko, Y., Chang, E., Jung, J., et al. (2021) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2021.10.05.463271 · Cited by 1
Cheng, T., Zhou, C., Pang, J., Tretyakova, N. Y., Tse, W. W., Liu, Y., & Liu, S. (2022) · Research Square · doi:10.21203/rs.3.rs-1432174/v2 · Cited by 1
Self-citationHow Clonal Hematopoiesis Can Predict Treatment Response in Patients With Dilated Cardiomyopathy
Sikking, M. A., & Verdonschot, J. A. J. (2024) · JACC Basic to Translational Science · doi:10.1016/j.jacbts.2024.06.002 · Cited by 1
IκBζ orchestrates the generation of effector-like CD8+ T cells to sustain antitumor immunityPreprint
Xuefeng, W. A. N. G., Chen, Y., Tang, Z., Wu, L., Li, X., Ma, Z., Jiang, H., Ji, X., Zang, Y., Gao, J., et al. (2026) · Research Square · doi:10.21203/rs.3.rs-8256869/v1 · Cited by 1
Self-citationVirus-Host Interactions in HIV-1 Pathogenesis and Viral Immune Evasion
Tsao, L.-C. (2019) · Carolina Digital Repository (University of North Carolina at Chapel Hill) · doi:10.17615/dth6-7m86
Myeloid-Derived Suppressor Cells in Aged Humans
Rauh, M. J., Cook, E. K., & Bowdish, D. M. E. (2017) · Springer eBooks · doi:10.1007/978-3-319-64597-1_96-1
Metadata
- Authors
- Zhang, Q., Zhao, K., Shen, Q., Han, Y., Gu, Y., Li, X., Zhao, D., Liu, Y., Wang, C., Zhang, X., Su, X., Liu, J., Ge, W., Levine, R. L., Li, N., & Cao, X.
- Affiliations
- Second Military Medical University (CN)
- Chinese Academy of Medical Sciences & Peking Union Medical College (CN)
- Memorial Sloan Kettering Cancer Center (US)
- Corresponding author
- Cao, Xuetao
- ORCID
- Venue
- Nature
- Published
- 2015-08-19
- Volume
- 525
- Issue
- 7569
- Pages
- 389-393
- ISSN
- 0028-0836 (ISSN-L)
- 1476-4687
- PMC
- PMC4697747
- OpenAlex
- W1171241794
- Cited by
- 807
- References
- 30
- Citations by year
- 2026: 56 · 2025: 77 · 2024: 83 · 2023: 89 · 2022: 93 · 2021: 82 · 2020: 79 · 2019: 85 · 2018: 62 · 2017: 50 · 2016: 43 · 2015: 7
- FWCI
- 23.46
- Type
- journal article
- Language
- en
- Open access
- green
- www.ncbi.nlm.nih.gov
- Licence
- www.springer.com/tdm (tdm)
- Locations
- Nature (publishedVersion)
- PubMed (publishedVersion)
- Europe PMC (PubMed Central) (acceptedVersion)
- PubMed Central (acceptedVersion)
- RePEc: Research Papers in Economics (submittedVersion)
- Funders
- National Cancer Institute (R01CA173636, P30CA008748)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Epigenetics and DNA Methylation
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Genomics and Chromatin Dynamics
- Life Sciences › Immunology and Microbiology › Immunology › Immune Response and Inflammation
- Keywords
- TET2, HDAC2, interleukin-6, inflammation resolution, histone deacetylation, transcriptional repression, 5-hydroxymethylcytosine, IκB, lipopolysaccharide, dendritic cells, macrophages, endotoxic shock, DSS-induced colitis
- MeSH terms
- Interleukin-6 Inhibitors, Acetylation, Animals, Chromatin, Colitis, Dendritic Cells, DNA-Binding Proteins, Female, Histones, Humans, Inflammation, Macrophages, Male, Mice, Inbred C57BL, Promoter Regions, Genetic, Proto-Oncogene Proteins, Transcription, Genetic, Down-Regulation, Interleukin-6, DNA Methylation, I-kappa B Proteins, Epigenesis, Genetic, Dioxygenases, Mice, Histone Deacetylase 2, HEK293 Cells
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
A language model drew the claims from the paper on 2026-11-12, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).
A second model labelled each claim on 2026-11-12 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).
Cited sources are checked with a language model’s help (qwen3.8-omni-flash).
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.